10.06.2015 • News

Chemours Spin-off from DuPont Finalized for July 1

DuPont’s board of directors has given final approval for the spin-off of the US group’s performance chemical business into a new standalone company known as The Chemours Company with effect from July 1, 2015.
In the spin-off, DuPont’s shareholders will receive one share of Chemours common stock for every five shares they hold in DuPont.
Trading of the shares is expected to begin on or about June 19 under the symbol “CC WI” on the New York Stock Exchange and continue through June 30.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.